Cargando…
B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders
Patients with B-non-Hodgkin lymphoma (NHL) are at increased risk of morbidity and mortality from SARS-CoV-2. We investigated the relationship between B cell cytopenia and the SARS-CoV-2 vaccine response in B-NHL patients. We measured anti-RBD antibodies and the lymphocyte immunophenotype in 19 contr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784616/ https://www.ncbi.nlm.nih.gov/pubmed/35105492 http://dx.doi.org/10.1016/j.vaccine.2022.01.040 |
_version_ | 1784638780259434496 |
---|---|
author | Tanguay, Mégane Boutin, Marianne Laumaea, Annemarie Salaciak, Matthew Mendoza, Alma Cassis, Chantal Ajjamada, Lissa Assouline, Sarit Patenaude, François Clark, Michael Webster Finzi, Andrés Johnson, Nathalie A. |
author_facet | Tanguay, Mégane Boutin, Marianne Laumaea, Annemarie Salaciak, Matthew Mendoza, Alma Cassis, Chantal Ajjamada, Lissa Assouline, Sarit Patenaude, François Clark, Michael Webster Finzi, Andrés Johnson, Nathalie A. |
author_sort | Tanguay, Mégane |
collection | PubMed |
description | Patients with B-non-Hodgkin lymphoma (NHL) are at increased risk of morbidity and mortality from SARS-CoV-2. We investigated the relationship between B cell cytopenia and the SARS-CoV-2 vaccine response in B-NHL patients. We measured anti-RBD antibodies and the lymphocyte immunophenotype in 19 controls, 22 lymphoma patients on observation (cohort 1) and 55 lymphoma patients receiving their vaccines post B-cell depleting therapy (cohort 2). Half of the lymphoma patients in both cohorts achieved seropositivity compared to 100% of controls. In cohort 2, only 5% achieved an antibody response in the first year post B-cell depleting treatment, vs 88% treated >2 years prior. Also, 28% of patients with <50 B cells/µl achieved a serologic response vs 86% of patients with B-cell >50 B cells/µl. B-cell cytopenia is profound within the first year of exposure to B-cell depleting treatment, therefore an additional dose of vaccine within that timeframe is unlikely to raise antibody levels. |
format | Online Article Text |
id | pubmed-8784616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87846162022-01-24 B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders Tanguay, Mégane Boutin, Marianne Laumaea, Annemarie Salaciak, Matthew Mendoza, Alma Cassis, Chantal Ajjamada, Lissa Assouline, Sarit Patenaude, François Clark, Michael Webster Finzi, Andrés Johnson, Nathalie A. Vaccine Short Communication Patients with B-non-Hodgkin lymphoma (NHL) are at increased risk of morbidity and mortality from SARS-CoV-2. We investigated the relationship between B cell cytopenia and the SARS-CoV-2 vaccine response in B-NHL patients. We measured anti-RBD antibodies and the lymphocyte immunophenotype in 19 controls, 22 lymphoma patients on observation (cohort 1) and 55 lymphoma patients receiving their vaccines post B-cell depleting therapy (cohort 2). Half of the lymphoma patients in both cohorts achieved seropositivity compared to 100% of controls. In cohort 2, only 5% achieved an antibody response in the first year post B-cell depleting treatment, vs 88% treated >2 years prior. Also, 28% of patients with <50 B cells/µl achieved a serologic response vs 86% of patients with B-cell >50 B cells/µl. B-cell cytopenia is profound within the first year of exposure to B-cell depleting treatment, therefore an additional dose of vaccine within that timeframe is unlikely to raise antibody levels. Elsevier Ltd. 2022-02-23 2022-01-24 /pmc/articles/PMC8784616/ /pubmed/35105492 http://dx.doi.org/10.1016/j.vaccine.2022.01.040 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Tanguay, Mégane Boutin, Marianne Laumaea, Annemarie Salaciak, Matthew Mendoza, Alma Cassis, Chantal Ajjamada, Lissa Assouline, Sarit Patenaude, François Clark, Michael Webster Finzi, Andrés Johnson, Nathalie A. B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders |
title | B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders |
title_full | B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders |
title_fullStr | B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders |
title_full_unstemmed | B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders |
title_short | B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders |
title_sort | b-cell cytopenia and time to last b-cell-depleting therapy predict response to sars-cov-2 vaccines in patients with lymphoproliferative disorders |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784616/ https://www.ncbi.nlm.nih.gov/pubmed/35105492 http://dx.doi.org/10.1016/j.vaccine.2022.01.040 |
work_keys_str_mv | AT tanguaymegane bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders AT boutinmarianne bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders AT laumaeaannemarie bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders AT salaciakmatthew bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders AT mendozaalma bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders AT cassischantal bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders AT ajjamadalissa bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders AT assoulinesarit bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders AT patenaudefrancois bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders AT clarkmichaelwebster bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders AT finziandres bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders AT johnsonnathaliea bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders |